Dr Rebecca Dent is Deputy CEO (Clinical) at the National Cancer Center Singapore (NCCS) at SingHealth and a senior consultant in the breast medical oncology service, as well as Professor at Duke-NUS Medical School. Her main research interest is in the field of breast cancer, focusing specifically on early, large operable, locally advanced and metastatic triple negative breast cancer (TNBC).
In February 2011, she began the next phase of her career as a consultant and now senior consultant at the National Cancer Center in Singapore (NCCS). Recognizing the need for a pan-Asian regional educational interaction she co-founded and co-chaired over fourteen Asia Pacific Breast Cancer Summits. This is a multidisciplinary meeting for the treatment of breast cancer which attracts over 2000 attendees from over 25 countries. She is a global PI and/or steering committee member for a number of large international trials in TNBC. This TNBC research has been cited extensively with the number of citations now more than 15,000 and an h-index of more than 60. She has serviced on the scientific Committee for numerous scientific committee meetings including the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and the San Antonio Breast Cancer Symposium (SABCS).
She is most proud to be the recipient of the ESMO Women for Oncology Award 2021 and was elected to serve on the ESMO Nomination Committee for 2023-2025 whose main responsibility is to select the next ESMO President. In 2024, she received the Duke-NUS Master Academic Clinician award and she served as the Scientific Chair for the ESMO Congress at Barcelona 2024. Most recently she serves on the Communication Committee for the American Society of Clinical Oncology from 2025-2028 and was inducted as a Fellow of the American Society of Clinical Oncology in 2025 (FASCO).